Charles Schwab’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Charles Schwab’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,486	Closed	-$5.5K	–	3702
2023 Q1	$5.5K	Hold	1,486	–	–	﹤0.01%	3547
2022 Q4	$5.65K	Hold	1,486	–	–	﹤0.01%	3544
2022 Q3	$12K	Hold	1,486	–	–	﹤0.01%	3505
2022 Q2	$32K	Buy	+1,486	New	+$34.9K	﹤0.01%	3461
2021 Q3	–	Sell	-786	Closed	-$76K	–	3554
2021 Q2	$76K	Sell	786 -1,272	-62%	-$141K	﹤0.01%	3316
2021 Q1	$305K	Hold	2,058	–	–	﹤0.01%	3236
2020 Q4	$288K	Hold	2,058	–	–	﹤0.01%	3173
2020 Q3	$313K	Sell	2,058 -116	-5%	-$18.9K	﹤0.01%	3015
2020 Q2	$382K	Buy	+2,174	New	+$364K	﹤0.01%	2942
2015 Q2	–	Sell	-77	Closed	-$79K	–	3133
2015 Q1	$79K	Hold	77	–	–	﹤0.01%	3049
2014 Q4	$258K	Hold	77	–	–	﹤0.01%	2907
2014 Q3	$225K	Hold	77	–	–	﹤0.01%	2909
2014 Q2	$294K	Buy	+77	New	+$290K	﹤0.01%	2869

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's NBSE Position: Q2 2023 in Review

Charles Schwab sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 1,486 shares — an estimated $5.5K sold.

Charles Schwab first reported a position in NBSE in Q2 2014 and held it in 13 quarters. The position peaked at $382K in Q2 2020. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Charles Schwab reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Charles Schwab sold 1,486 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.5K.
Charles Schwab first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 13 quarters.
Charles Schwab's NeuBase Therapeutics, Inc. Common Stock position peaked at $382K in Q2 2020.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.